Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Ipamorelin: Evidence Summary
Evidence summary for Ipamorelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Ipamorelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| GH secretion | Tier B | 6 | Well-characterized selective GH secretagogue in Phase II trials with dose-dependent GH release |
| Post-operative recovery | Tier B | 2 | Phase II RCTs for post-operative ileus — safe but primary endpoints not met |
| Anti-aging | Tier D | 0 | Theoretical based on GH optimization, no direct evidence |
| Body composition | Tier D | 0 | No RCTs measuring lean mass, fat mass, or strength outcomes |
References (11)
- Ipamorelin, the first selective growth hormone secretagogue — Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH . European Journal of Endocrinology (1998) DOI: 10.1530/eje.0.1390552
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients — Beck DE, Sweeney WB, McCarter MD . International Journal of Colorectal Disease (2014) PMID: 25331030
- Growth hormone secretagogues: history, mechanism of action, and clinical development — Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S . JCSM Rapid Communications (2020) DOI: 10.1002/rco2.9
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Jeschke J, Lipshultz LI, Kovac JR . Translational Andrology and Urology (2020) PMID: 32257855
- Pharmacological characterisation of a new oral GH secretagogue, NN703 — Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M . European Journal of Endocrinology (1999) PMID: 10427162
- Growth hormone secretagogue receptor family members and ligands — Smith RG . Endocrine (2005) DOI: 10.1385/ENDO:28:1:009
- Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function — Helsinn Therapeutics (U.S.), Inc . ClinicalTrials.gov (2011) NCT01280344
- Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus — Helsinn Therapeutics (U.S.), Inc . ClinicalTrials.gov (2008) NCT00672074
- Ghrelin is a growth-hormone-releasing acylated peptide from stomach — Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Nature (1999) PMID: 10604470
- Growth hormone-releasing peptides — Ghigo E, Arvat E, Muccioli G, Camanni F . European Journal of Endocrinology (1997) PMID: 9186261
- Modeling study of ipamorelin SC50 for half-maximal GH release — Various . Endocrinology (1999) PMID: 10496658